within Pharmacolibrary.Drugs.S_SensoryOrgans.S01C_AntiinflammatoryAgentsAndAntiinfectivesInCombination.S01CB03_Hydrocortisone;

model Hydrocortisone
  extends Pharmacolibrary.Drugs.ATC.S.S01CB03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>S01CB03</td></tr><td>route:</td><td>ophthalmic</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Hydrocortisone is a corticosteroid hormone (glucocorticoid) used to treat inflammation, allergic reactions, adrenal insufficiency, and various eye conditions. The ophthalmic formulation (ATC code S01CB03) is approved and is commonly used today for treating ocular inflammation.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for topical ophthalmic hydrocortisone. Ocular drugs generally exhibit limited systemic absorption, so PK parameters here are approximated based on literature for ocular corticosteroids, as no direct detailed PK profiles are available for ophthalmic hydrocortisone.</p><h4>References</h4><ol><li><p>Edelman, JL (2010). Differentiating intraocular glucocorticoids. <i>Ophthalmologica. Journal international d&#x27;ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde</i> 224 Suppl 1 25–30. DOI:<a href=\"https://doi.org/10.1159/000315158\">10.1159/000315158</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20714178/\">https://pubmed.ncbi.nlm.nih.gov/20714178</a></p></li><li><p>Álvarez-Álvarez, L, et al., &amp; Lago, F (2019). Hydrocortisone loaded poly-(3-hydroxybutyrate-co-3-hydroxyvalerate) nanoparticles for topical ophthalmic administration: Preparation, characterization and evaluation of ophthalmic toxicity. <i>International journal of pharmaceutics</i> 568 118519–None. DOI:<a href=\"https://doi.org/10.1016/j.ijpharm.2019.118519\">10.1016/j.ijpharm.2019.118519</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31310791/\">https://pubmed.ncbi.nlm.nih.gov/31310791</a></p></li><li><p>Yang, X, et al., &amp; Mitra, AK (2016). Nanoparticle-Based Topical Ophthalmic Gel Formulation for Sustained Release of Hydrocortisone Butyrate. <i>AAPS PharmSciTech</i> 17(2) 294–306. DOI:<a href=\"https://doi.org/10.1208/s12249-015-0354-5\">10.1208/s12249-015-0354-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26085051/\">https://pubmed.ncbi.nlm.nih.gov/26085051</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Hydrocortisone;
